• Cash balance of €12.2 million at quarter end
• Net cash outflow of €1.6 million, lower than prior year
• Strong customer receipts of €4.2 million in the quarter

Oneview Healthcare PLC (ASX:ONE) released its Appendix 4C - Quarterly Cashflow report for the quarter ending 31 March 2025 (Q1 25). The company's cash balance at 31 March 2025 was €12.2 million (A$21.0m), compared to €13.8 million (A$23.2 million) at 31 December 2024. The company had a net cash outflow of €1.6 million during the quarter, compared to an outflow of €2.1 million in the same quarter of the prior year. The lower outflow was primarily due to strong customer receipts inflows in the first quarter of 2025 of €4.2 million, compared to €2.6 million during the same quarter of the prior year. Product manufacturing and operating costs were slightly higher in the quarter compared to the same quarter in the prior year due to greater deployment activity. The company also had marginally higher staff and admin costs for the quarter compared to the same quarter in the prior year. Oneview continued to progress implementation projects at existing customer sites, including Inova Health and Rady Children's Health. The company also launched its new Virtual Patient Assistant 'alpha' product called Ovie during the quarter.

The company has not experienced any project delays as a result of the tariff changes proposed by the new US administration. Based on the current scope of the proposed tariffs, Oneview expects the direct impact of the tariffs on its business to be limited to its current sourcing of some hardware items from China. The company's strong levels of pre-tariff inventory of these items could be a strong competitive advantage as it faces a more uncertain economic environment. Critically, Oneview's recurring software revenue will not be impacted.